Outcome | Extrafine-particle ICSa (n = 1399) | Fine-particle ICSb (n = 1399) | p-value |
---|---|---|---|
Asthma control | |||
Risk-domain asthma control, n (%) | 1236 (88) | 1129 (81) | <0.001 |
Overall asthma control, n (%) | 1091 (78) | 934 (67) | <0.001 |
Severe exacerbations, n (%) | |||
0, n (%) | 1236 (88) | 1129 (81) | <0.001 |
1, n (%) | 108 (8) | 184 (13) | |
2+, n (%) | 55 (4) | 86 (6) | |
Treatment stability, n (%) | 809 (58) | 560 (40) | <0.001 |
Prescribed average daily dose of SABA, μg/d, n (%) | |||
0 μg/d, n (%) | 686 (49) | 461 (33) | <0.001 |
1–100 μg/d, n (%) | 326 (23) | 343 (25) | |
101 μg/d+, n (%) | 387 (28) | 595 (43) | |
1+ prescriptions of antifungal for candidiasis, n (%) | 48 (3) | 45 (3) | 0.753 |
1+ asthma-related hospital admissions, n (%) | 19 (1) | 16 (1) | 0.613 |
Respiratory medications in outcome period | |||
Courses of acute oral corticosteroids, n (%) | |||
0, n (%) | 1246 (89) | 1135 (81) | <0.001 |
1, n (%) | 102 (7) | 182 (13) | |
2+, n (%) | 51 (5) | 82 (6) | |
SABA prescriptions, n (%) | |||
0, n (%) | 686 (49) | 461 (33) | <0.001 |
1, n (%) | 245 (18) | 235 (17) | |
2, n (%) | 180 (13) | 218 (16) | |
3+, n (%) | 288 (21) | 485 (35) | |
ICS prescriptions (including initial prescription) | |||
2, n (%) | 0 (0) | 0 (0) | 0.022 |
3, n (%) | 462 (33) | 520 (37) | |
4+, n (%) | 937 (67) | 879 (63) | |
Average ICS daily dose (μg/d, fluticasone-equivalentsc) | |||
0–150 μg/d, n (%) | 460 (33) | 263 (19) | <0.001 |
151–250 μg/d, n (%) | 484 (35) | 416 (30) | |
251–450 μg/d, n (%) | 358 (26) | 401 (29) | |
451 μg/d+, n (%) | 97 (7) | 319 (23) | |
Average ICS daily dose (μg/d, EF-HFA-BDP/ciclesonide equivalent dosed), median (IQR) | 185 (132–290) | 272 (178–410) | <0.001 |
Average ICS daily dose (μg/d, EF-HFA-BDP/ciclesonide equivalent dosed) | |||
0–150 μg/d, n (%) | 460 (33) | 263 (19) | <0.001 |
151–250 μg/d, n (%) | 484 (35) | 416 (30) | |
251–450 μg/d, n (%) | 358 (26) | 401 (29) | |
451 μg/d+, n (%) | 97 (7) | 319 (23) | |
LABA prescriptions in outcome period | 770 (55) | 875 (63) | <0.001 |
LTRA prescriptions in outcome period | 83 (6) | 47 (3) | 0.001 |